No matches
Dermatology

The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.
Alan Irvine
Amy Paller
Jean-David Bouaziz
MD
Alan Irvine +2 more

Related resources

Mast Cells and the Neuroimmune Axis in CSU

Mast Cells and the Neuroimmune Axis in CSU

expert video
UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

UCARE 2023: Potential Role of Type 2 Cytokines in CSU Pathogenesis

expert video
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

expert video
Disease Modification in AD

Disease Modification in AD

expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

expert video
The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

expert video
The Impact of Skin Dysbiosis on Atopic Dermatitis

The Impact of Skin Dysbiosis on Atopic Dermatitis

expert video
The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

The Association Between Epidermal Barrier Dysfunction and S. aureus Colonization in Atopic Dermatitis

expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

expert video
Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

Infographic
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

expert video
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

expert video
Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

expert video
Differences in Itch in AD, PN, and CSU

Differences in Itch in AD, PN, and CSU

expert video
Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

Contribution of Type 2 Cytokines to Inflammation and Itch in AD, PN, and CSU 

expert video
Itch in AD, PN and CSU: Role of Type 2 Inflammation

Itch in AD, PN and CSU: Role of Type 2 Inflammation

expert video
Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

expert video
Shared and Unique Characteristics of AD, PN, and CSU

Shared and Unique Characteristics of AD, PN, and CSU

expert video
Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Infographic
Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

Emerging Understanding of Chronic Itchy Skin Diseases: Shared and Unique Drivers in AD, PN, and CSU

expert video
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroimmune Axis in Atopic Dermatitis

Neuroimmune Axis in Atopic Dermatitis

expert video
UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

UCARE 2023: Immune Cells and Mediators Essential for Driving CSU Pathology

expert video
UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

expert video
UCARE 2023: Neuronal Involvement in CSU

UCARE 2023: Neuronal Involvement in CSU

expert video
UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis 

expert video
Comorbidities and Disease Burden in CSU

Comorbidities and Disease Burden in CSU

expert video
The Role of Chronic Inflammation in the Pathogenesis of CSU

The Role of Chronic Inflammation in the Pathogenesis of CSU

expert video
AD, PN, and CSU: Distinct, Pruritic Diseases

AD, PN, and CSU: Distinct, Pruritic Diseases

expert video
Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

Infographic
Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

expert video
Disease-Specific Aspects of Itch in AD, PN, and CSU

Disease-Specific Aspects of Itch in AD, PN, and CSU

expert video
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

expert video
Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

expert video
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

expert video
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

expert video
A brief overview of the pathophysiology of PN

A brief overview of the pathophysiology of PN

expert video
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

expert video
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

expert video
Neuroimmune Axis and Neuroinflammation in PN

Neuroimmune Axis and Neuroinflammation in PN

expert video
Current systemic therapies have been shown to induce remission in a subset of AD patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

expert video
Can advanced systemic therapies modify pathomechanisms in AD?

Can advanced systemic therapies modify pathomechanisms in AD?

expert video

Learning objectives

  • Highlight the cumulative impact of type 2 inflammation on the lives of patients with AD, beyond signs and symptoms
  • Explore the concepts of disease modification and early intervention and how biomarkers might help inform management of AD
  • Investigate the potential of targeting type 2 inflammation to achieve disease modification, including impact on atopic and non-atopic comorbidities
Tags
biomarkersdisease modificationpediatric
MAT-GLB-2506011 - 1.0 - 10/2025

About these experts

Dermatology
MD

Alan Irvine

Professor of Dermatology, Trinity College, Dublin, Ireland

Dermatology
MD, MS

Amy Paller

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

Dermatology
MD, PhD

Jean-David Bouaziz

Professor of Dermatology, Université Paris Cité Head of the Department of Dermatology | Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region